Azurity Pharmaceuticals Inc

07/10/2019 | Press release | Archived content

FDA Approves KaterziaTM, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Azurity Pharmaceuticals Inc published this content on July 10, 2019, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 07, 2026 at 13:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]